WebOur Active Trials. Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) ClinicalTrials.gov Identifier: NCT04495556. Principal Investigator: Peter Calabresi, M.D. The Use of Technology to Improve MS Clinical Trials and Patient Care. ClinicalTrials.gov Identifier: NCT02454907. WebAug 5, 2024 · The objective of the REPAIR clinical trial program was to demonstrate the effects of Clene’s energy-enhancing nanotherapeutic, CNM-Au8 ®, on brain energy metabolites in two sister studies of...
The Latest on MS Clinical Trials: What
WebChariotMS is the first clinical trial specifically for people with advanced MS. It’s testing whether the drug cladribine can help people with more advanced MS maintain the use of … WebMS clinical trials usually use walking ability as the key measurement for whether a treatment is effective, Howe explains – so people who use wheelchairs have been left out. But the ChariotMS phase II trial will test whether cladribine can help people who can’t walk maintain the use of their arms, so will need a different test. Researchers ... linkedin professional profile builder
Chariot: Pro - Alzheimer’s Treatment News - Johnson
WebFeb 19, 2024 · A Study to Assess CART19 for B Cell Malignancies. The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 … WebThe DIAmOND Clinical Trial. The DIAmOND study is for patients with metastatic HER-2 positive breast cancer, which is a tumour type that tends to respond better to … ChariotMS will recruit 200 people who have an EDSS (Expanded Disability Status Scale)score of 6.5 to 8.5. This means they can’t walk further than 20 meters with two crutches, or are unable to walk at all, but still have some use of their arms and hands. Eligible participants will be randomly assigned to take either … See more Yes! If you have advanced progressive MS and an EDSS (Expanded Disability Status Scale)score of 6.5 to 8.5 the researchers want to hear from you. EDSS 6.5 - 8.5 means you can’t walk further than 20 meters with two … See more Thanks to research, there are over a dozen licensed disease modifying therapies for people with relapsing MS, and some emerging for early progressive MS. But traditionally, … See more The race is on to find treatments that will slow or even stop disability progression in MS. You can help speed up the process by supporting projects like this. Donate today to help stop MS See more linkedin professor eduardo navarro